Top Key Companies for Adeno-Associated Virus (AAV) Gene Therapy Market: Creative Biolabs, Affinia Therapeutics, Spark Therapeutics, AGC Biologics, StrideBio, SIRION Biotech, Neurophth Biotechnology, Belief BioMed, BiBo Biopharma Engineering Co., LTD., Beihai Kangcheng, PackGene Biotech, Sarepta Therapeutics, Carbon BioSciences, Kelonia Therapeutics, Roche, Remedium Bio.
Global Adeno-Associated Virus (AAV) Gene Therapy Market Size was estimated at USD 300.7 million in 2022 and is projected to reach USD 421.74 million by 2028, exhibiting a CAGR of 5.8% during the forecast period.
Global Adeno-Associated Virus (AAV) Gene Therapy Market Overview And Scope:
The Global Adeno-Associated Virus (AAV) Gene Therapy Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Adeno-Associated Virus (AAV) Gene Therapy utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Adeno-Associated Virus (AAV) Gene Therapy Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adeno-Associated Virus (AAV) Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Adeno-Associated Virus (AAV) Gene Therapy market.
Global Adeno-Associated Virus (AAV) Gene Therapy Market Segmentation
By Type, Adeno-Associated Virus (AAV) Gene Therapy market has been segmented into:
Luxturna
Zolgensma
Others
By Application, Adeno-Associated Virus (AAV) Gene Therapy market has been segmented into:
Central Nervous System Diseases
Ocular Diseases
Liver-directed Diseases
Other Hereditary Diseases
Regional Analysis of Adeno-Associated Virus (AAV) Gene Therapy Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Adeno-Associated Virus (AAV) Gene Therapy Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Adeno-Associated Virus (AAV) Gene Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Adeno-Associated Virus (AAV) Gene Therapy market.
Top Key Companies Covered in Adeno-Associated Virus (AAV) Gene Therapy market are:
Creative Biolabs
Affinia Therapeutics
Spark Therapeutics
AGC Biologics
StrideBio
SIRION Biotech
Neurophth Biotechnology
Belief BioMed
BiBo Biopharma Engineering Co.
LTD.
Beihai Kangcheng
PackGene Biotech
Sarepta Therapeutics
Carbon BioSciences
Kelonia Therapeutics
Roche
Remedium Bio
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Adeno-Associated Virus (AAV) Gene Therapy Market by Type
5.1 Adeno-Associated Virus (AAV) Gene Therapy Market Overview Snapshot and Growth Engine
5.2 Adeno-Associated Virus (AAV) Gene Therapy Market Overview
5.3 Luxturna
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Luxturna: Geographic Segmentation
5.4 Zolgensma
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Zolgensma: Geographic Segmentation
5.5 Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others: Geographic Segmentation
Chapter 6: Adeno-Associated Virus (AAV) Gene Therapy Market by Application
6.1 Adeno-Associated Virus (AAV) Gene Therapy Market Overview Snapshot and Growth Engine
6.2 Adeno-Associated Virus (AAV) Gene Therapy Market Overview
6.3 Central Nervous System Diseases
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Central Nervous System Diseases: Geographic Segmentation
6.4 Ocular Diseases
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Ocular Diseases: Geographic Segmentation
6.5 Liver-directed Diseases
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Liver-directed Diseases: Geographic Segmentation
6.6 Other Hereditary Diseases
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2026-2035F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other Hereditary Diseases: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Adeno-Associated Virus (AAV) Gene Therapy Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Adeno-Associated Virus (AAV) Gene Therapy Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 CREATIVE BIOLABS
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 AFFINIA THERAPEUTICS
7.4 SPARK THERAPEUTICS
7.5 AGC BIOLOGICS
7.6 STRIDEBIO
7.7 SIRION BIOTECH
7.8 NEUROPHTH BIOTECHNOLOGY
7.9 BELIEF BIOMED
7.10 BIBO BIOPHARMA ENGINEERING CO.
7.11 LTD.
7.12 BEIHAI KANGCHENG
7.13 PACKGENE BIOTECH
7.14 SAREPTA THERAPEUTICS
7.15 CARBON BIOSCIENCES
7.16 KELONIA THERAPEUTICS
7.17 ROCHE
7.18 REMEDIUM BIO
Chapter 8: Global Adeno-Associated Virus (AAV) Gene Therapy Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Luxturna
8.2.2 Zolgensma
8.2.3 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Central Nervous System Diseases
8.3.2 Ocular Diseases
8.3.3 Liver-directed Diseases
8.3.4 Other Hereditary Diseases
Chapter 9: North America Adeno-Associated Virus (AAV) Gene Therapy Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Luxturna
9.4.2 Zolgensma
9.4.3 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Central Nervous System Diseases
9.5.2 Ocular Diseases
9.5.3 Liver-directed Diseases
9.5.4 Other Hereditary Diseases
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Adeno-Associated Virus (AAV) Gene Therapy Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Luxturna
10.4.2 Zolgensma
10.4.3 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Central Nervous System Diseases
10.5.2 Ocular Diseases
10.5.3 Liver-directed Diseases
10.5.4 Other Hereditary Diseases
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Adeno-Associated Virus (AAV) Gene Therapy Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Luxturna
11.4.2 Zolgensma
11.4.3 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Central Nervous System Diseases
11.5.2 Ocular Diseases
11.5.3 Liver-directed Diseases
11.5.4 Other Hereditary Diseases
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Luxturna
12.4.2 Zolgensma
12.4.3 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Central Nervous System Diseases
12.5.2 Ocular Diseases
12.5.3 Liver-directed Diseases
12.5.4 Other Hereditary Diseases
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Luxturna
13.4.2 Zolgensma
13.4.3 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Central Nervous System Diseases
13.5.2 Ocular Diseases
13.5.3 Liver-directed Diseases
13.5.4 Other Hereditary Diseases
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Adeno-Associated Virus (AAV) Gene Therapy Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Luxturna
14.4.2 Zolgensma
14.4.3 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Central Nervous System Diseases
14.5.2 Ocular Diseases
14.5.3 Liver-directed Diseases
14.5.4 Other Hereditary Diseases
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Adeno-Associated Virus (AAV) Gene Therapy Scope:
|
Report Data
|
Adeno-Associated Virus (AAV) Gene Therapy Market
|
|
Adeno-Associated Virus (AAV) Gene Therapy Market Size in 2025
|
USD XX million
|
|
Adeno-Associated Virus (AAV) Gene Therapy CAGR 2025 - 2032
|
XX%
|
|
Adeno-Associated Virus (AAV) Gene Therapy Base Year
|
2024
|
|
Adeno-Associated Virus (AAV) Gene Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Creative Biolabs, Affinia Therapeutics, Spark Therapeutics, AGC Biologics, StrideBio, SIRION Biotech, Neurophth Biotechnology, Belief BioMed, BiBo Biopharma Engineering Co., LTD., Beihai Kangcheng, PackGene Biotech, Sarepta Therapeutics, Carbon BioSciences, Kelonia Therapeutics, Roche, Remedium Bio.
|
|
Key Segments
|
By Type
Luxturna
Zolgensma
Others
By Applications
Central Nervous System Diseases
Ocular Diseases
Liver-directed Diseases
Other Hereditary Diseases
|
